Bristol Myers Squibb Headquarters: New York, New York, USA Number of employees: 19,437 Year founded: 1887 Revenue (2025): $48.2 billion Forbes overall rank: 523 Bristol Myers Squibb (BMS) earned roughly $48.2 billion in 2025, with growth driven by products such as PD-1 inhibitor Opdivo (nivolumab), CTLA-4 inhibitor Yervoy (ipilimumab), anemia drug Reblozyl (luspatercept-aamt) and Camzyos (mavacamten) for obstructive hypertrophic cardiomyopathy (oHCM), though overall sales have been pressured by patent expirations and pricing reforms
Are you wondering how to handle loose, sagging skin and stretch marks due to fast and excessive weight loss
Medi-Peel avoids harmful chemicals and opts for sustainable solutions at every stage of production
Inform your provider about the complete clinical picture , including the timing of symptom onset relative to Zepbound initiation or dose changes, severity and pattern of breathing difficulties, and any accompanying symptoms such as gastrointestinal distress, palpitations, or lightheadedness
Self-extracellular RNA promotes pro-inflammatory response of astrocytes to exogenous and endogenous danger signals
Protocols should only be conducted in properly equipped laboratory environments by qualified researchers
